Loading...
Loading...
VERV| Name | Value |
|---|---|
| Revenues | 6.7M |
| Cost of Revenue | 1.7M |
| Gross Profit | 5.0M |
| Operating Expense | 63.9M |
| Operating I/L | -58.8M |
| Other Income/Expense | 9.1M |
| Interest Income | 7.4M |
| Pretax | -49.7M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -49.8M |
Verve Therapeutics, Inc. is a genetic medicines company specializing in developing gene editing treatments for cardiovascular diseases. Its lead product candidate, VERVE-101, offers a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also focuses on the development of the ANGPTL3 program, which aims to permanently turn off the ANGPTL3 gene in the liver. Verve Therapeutics, Inc. has collaboration and license agreements with Beam Therapeutics Inc., Acuitas Therapeutics, Inc., and The Broad Institute and the President and Fellows of Harvard College for Cas9 technology.
